Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
OPERATING ACTIVITIES    
Net loss: $ (1,112) $ (324)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Provision for doubtful accounts (130) 114
Depreciation 2,652 2,955
(Gain) loss on disposal of and reserve adjustments for medical equipment (43) 450
Gain on sale of medical equipment (629) (883)
Amortization of intangible assets 248 248
Amortization of deferred debt issuance costs 19 18
Stock-based compensation 1,057 720
Deferred income taxes (186) (302)
Changes in assets - (increase)/decrease:    
Accounts receivable (237) (961)
Inventories 153 (823)
Other current assets (685) (830)
Other assets 376 (846)
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (1,106) 313
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 377 (151)
INVESTING ACTIVITIES    
Purchase of medical equipment (1,493) (3,968)
Purchase of property and equipment (182) (317)
Proceeds from sale of medical equipment, property and equipment 1,257 1,234
NET CASH USED IN INVESTING ACTIVITIES (418) (3,051)
FINANCING ACTIVITIES    
Principal payments on long-term debt (15,258) (13,683)
Cash proceeds from long-term debt 16,069 16,894
Common stock repurchased as part of share repurchase program 0 (153)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (365) (324)
Cash proceeds from exercise of options and ESPP 186 559
NET CASH PROVIDED BY FINANCING ACTIVITIES 632 3,293
Net change in cash and cash equivalents 591 91
Cash and cash equivalents, beginning of period 231 165
Cash and cash equivalents, end of period $ 822 $ 256